MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient With Acquired RET Rearrangement

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.540
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

BLU-667 Targets RET-Altered Cancers

Cancer Discovery
Oncology
2018English

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

TBC1D32-RET: A Novel RET Oncogenic Fusion in Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Discovery of Wt RET and V804M RET Inhibitors: From Hit to Lead

ChemMedChem
Organic ChemistryMolecular MedicinePharmacologyBiochemistryToxicologyDrug DiscoveryPharmaceutics
2017English

C-Ret Molecule in Malignant Melanoma From Oncogenic RET-Carrying Transgenic Mice and Human Cell Lines

PLoS ONE
Multidisciplinary
2010English

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy